(Q24245544)

1

0 references

Jeroen Lijmer

2

0 references

Ferdi Balk

3

0 references

Willem A Nolen

Cochrane Database of Systematic Reviews

5

0 references

publication date

19 October 2005

0 references

published in

0 references

cites work

A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

The pharmacological treatment of delusional depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

Rapid reversal of psychotic depression using mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

Limited efficacy of ketoconazole in treatment-refractory major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

Delusional depression*Phenomenology, neuroendocrine function, and tricyclic antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

Who benefits from electroconvulsive therapy? Combined results of the Leicester and Northwick Park trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

The validity of major depression with psychotic features based on a community study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

Prevalence of depressive episodes with psychotic features in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

Psychotic (delusional) depression: a meta-analysis of physical treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

Medication resistance and clinical response to electroconvulsive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

Effect of antidepressant medication resistance on short-term response to electroconvulsive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

Somatic treatment of psychotic depression: review and recommendations for practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

7 January 2021

Imipramine (Tofranil vs. placebo in hospitalized psychotic depressives. (a comparison of patients' self-ratings, psychiatrists' ratings and psychological test scores)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

7 January 2021

Placebo response rates in psychotic and nonpsychotic depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

7 January 2021

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

7 January 2021

A Placebo-controlled Study of the Antidepressant Activity of Moclobemide,A New MAO-A Inhibitor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

7 January 2021

Lithium-TCA combination treatment of psychotic depression: comparison with TCA-neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

7 January 2021

Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

7 January 2021

The clinical and neuroendocrine features of psychotic depression.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

7 January 2021

Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

7 January 2021

Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

7 January 2021

Resistance to antidepressant medications and short-term clinical response to ECT

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

7 January 2021

Venlafaxine Versus Fluvoxamine in the Treatment of Delusional Depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

7 January 2021

A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004044.PUB2

7 January 2021